原发性中枢神经系统淋巴瘤(PCNSL):MRI反应标准修订

• 作 者: Küker W. Ngele T. Thiel E. 刘康永
• 机 构: Department of Neuroradiology Radcliffe Infirmary Woodstock Road Oxford OX2 6HE United Kingdom.Dr,
• 出 处: 世界核心医学期刊文摘(神经病学分册)
• 发表日期: 2006年02期
• 关键词: MRI PCNSL 标准修订 肿瘤进展 淋巴瘤 生物活性

The authors investigated the applicability of Macdonald response criteria to patients with primary CNS lymphoma (PCNSL). Four of 68 patients with persisting contrast-enhancing lesions after primary therapy did not receive further therapy, and none showed tumor progression after up to 54 months. Because contrast enhancement may not necessarily indicate residual, biologically active lymphoma, the authors propose a modification of the Macdonald response criteria.

The authors investigated the applicability of Macdonald response criteria to patients with primary CNS lymphoma (PCNSL). Four of 68 patients with persisting contrast-enhancing lesions after not receiving further therapy, and no showed tumor progression after up to 54 months. Because contrast enhancement may not necessarily indicate residual, biologically active lymphoma, the authors propose a modification of the Macdonald response criteria.